SEC Company Response from Inhibitor Therapeutics, Inc. (INTI) (CIK 0001042418) (INTI) — Apr 30, 2008
Inhibitor Therapeutics, Inc. (INTI) (CIK 0001042418)
Date: April 30, 2008 · CIK: 0001042418 · Accession: 0001193125-08-097386
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-148942
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 Re: Commonwealth Biotechnologies, Inc. Registration Statement on Form S-1 File No: 333-148942
Dear Mr. Riedler:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned requests acceleration of the effective date of the above-captioned Registration Statement to 5:00 p.m., Eastern Daylight Time, on April 30, 2008 or as soon thereafter as practicable.
In connection with this request, the undersigned acknowledges as follows:
•
should the Securities and Exchange Commission (“SEC”) or the staff of the SEC, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the SEC from taking any action with respect to the filing;
•
the action of the SEC or the staff of the SEC, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the undersigned from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the undersigned may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.
Sincerely,
COMMONWEALTH BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESPONDENCE April 30, 2008 By EDGAR Jeffrey P. Riedler, Esq. Assistant Director Division of Corporation Finance Securities and Exchange Commission Mail Stop 3561 100 F Street, N.E. Washington, D.C. 20549 Re: Commonwealth Biotechnologies, Inc. Registration Statement on Form S-1 File No: 333-148942 Dear Mr. Riedler: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned requests acceleration of the effective date of the above-captioned Registration Statement to 5:00 p.m., Eastern Daylight Time, on April 30, 2008 or as soon thereafter as practicable. In connection with this request, the undersigned acknowledges as follows: • should the Securities and Exchange Commission (“SEC”) or the staff of the SEC, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the SEC from taking any action with respect to the filing; • the action of the SEC or the staff of the SEC, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the undersigned from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the undersigned may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States. Sincerely, COMMONWEALTH BIOTECHNOLOGIES, INC. By: /s/ Paul D’Sylva, Ph.D. Paul D’Sylva, Ph.D. Chief Executive Officer cc: Rose Zukin, Esq.